The effect of anti TNF alpha (certolizumab) treatment on insulin resistance, lipid parameters and cardiovascular risk in patients with axial spondyloarthritis (ankylosing spondylitis)

Authors : Hasan GÖĞEBAKAN, Gözde YILDIRIM ÇETİN

Pages : 65-72

Doi:10.56016/dahudermj.1146178

View : 17 | Download : 7

Publication Date : 2022-07-29

Article Type : Research Paper

Abstract :Objectives: To evaluate the effects of certolizumab treatment on insulin resistance insert ignore into journalissuearticles values(IR);, lipid parameters, and cardiovascular insert ignore into journalissuearticles values(CV); risk in patients with ankylosing spondylitis insert ignore into journalissuearticles values(AS);. Methods: This prospective study included 80 consecutive patients with AS insert ignore into journalissuearticles values(52 males, 28 females); and 74 control subjects insert ignore into journalissuearticles values(48 males, 26 feemales);. The AS patients and control group were compared in respect of basal values. All AS patients with active disease were treated with certolizumab. Biochemical profiles were obtained before and after 24 weeks of certolizumab treatment. Homeostatic model assessment-insulin resistance insert ignore into journalissuearticles values(HOMA-IR); was used to measure IR and the quantitative insulin sensitivity control index insert ignore into journalissuearticles values(QUICKI); was used to measure insulin sensitivity. The Framingham equation was used to evaluate CV risk factors. Results: A statistically significant increase was determined in total cholesterol insert ignore into journalissuearticles values(TC);, high-density lipoprotein cholesterol insert ignore into journalissuearticles values(HDL-C);, and triglyceride insert ignore into journalissuearticles values(TG); values after 24 weeks of certolizumab treatment. No statistically significant change was determined in the plasma atherogenic index insert ignore into journalissuearticles values(PAI); and low-density lipoprotein cholesterol insert ignore into journalissuearticles values(LDL-C); values. A statistically significant decrease was determined in HOMA-IR and an increase in QUICKI. When the Framingham risk scoring was compared with the baseline values, a statistically significant decrease in risk was found at week 24. Conclusions: Certolizumab therapy was associated with a significant increase in HDL-C, TC, and TG levels without any significant change in PAI and LDL-C, and was determined to increase insulin sensitivity and lower insulin resistance. There was also a significant reduction in SBP and 10-year Framingham risk scores at 24 weeks after the start of certolizumab therapy.
Keywords : Ankylosing spondylitis, Certolizumab, İnsulin resistance, Framingham risk scoring, Lipid parameters, Ankylosing spondylitis, Certolizumab, İnsulin resistance, Framingham risk scoring, Lipid parameters